$PFE Pfizer announces the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines. Two studies of the 20-valent pneumococcal polysaccharide conjugate vaccine candidate. One study of the respiratory syncytial virus (RSV) vaccine candidate